Assorted News from the Last Week: NCI’s Childhood Cancer Data Initiative has grown since its launch in 2019. Read about the initiative’s activities, successes, and

Assorted News from the Last Week: The FDA’s Oncologic Drugs Advisory Committee (ODAC) met on June 16, 2023, to discuss considerations for dose optimization of

Assorted News from the Last Week: National Comprehensive Cancer Network releases statement addressing ongoing chemotherapy shortages. Childhood cancer survivors at increased risk for sleep concerns

Assorted News from the Last Week: A paper explaining NCI’s Childhood Cancer Data Initiative’s (CCDI) accomplishments to date and discussing priorities for the future of the

Happy Memorial Day! Assorted News from the Last Week: Researchers found that the probability of FDA approval within 10 years was 10.4%, but the probability

Assorted News from the Last Week: About one-third of children and two-thirds of adults with relapsed or refractory neuroblastoma responded to single-agent lorlatinib. Bereaved parents

Assorted News from the Last Week: Childhood cancer survivors have increased rates of late, major surgeries—Magnitude of the risk is “striking.” As the US faces

Assorted News from the Last Week: Analysis finds found that “excellent” survival outcomes were achieved in patients receiving reduced treatment for neuroblastoma as a result

Assorted News from the Last Week: Adding a postinduction course of blinatumomab (Blincyto) to chemotherapy appeared safe and highly effective for treating an aggressive form